Macitentan

證據等級: L5

預測適應症: 10 個

Macitentan: From Pulmonary Arterial Hypertension to Pulmonary Arteriovenous Malformation

One-Sentence Summary

Macitentan (Opsumit®) is a dual endothelin receptor antagonist (ERA) with established global approval for pulmonary arterial hypertension (PAH), though it carries no Singapore registration to date. The TxGNN model ranks pulmonary arteriovenous malformation (PAVM) as its highest-scoring new indication (98.89%), yet this prediction is backed by no clinical trials and no published literature, and the mechanistic rationale is not compelling. Of the 10 TxGNN predictions in this evidence pack, two PAH subtypes — CHD-associated PAH (rank #2) and connective tissue disease-associated PAH (rank #5) — carry substantially stronger evidence (L3 each) and represent the more clinically actionable repurposing opportunities.

Quick Overview

Item	Content
Original Indication	Pulmonary Arterial Hypertension (globally approved; not registered in Singapore)
Predicted New Indication	Pulmonary Arteriovenous Malformation (PAVM)
TxGNN Prediction Score	98.89%
Evidence Level	L5
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Macitentan is a dual endothelin receptor antagonist that binds both ETA and ETB receptors with high affinity and unusually slow receptor-dissociation kinetics — a pharmacological feature that distinguishes it from earlier ERA agents such as bosentan. In pulmonary vascular disease, the ET-1 axis is a key driver of vasoconstriction, smooth muscle proliferation, and adventitial fibrosis. By blocking both receptor subtypes, Macitentan reduces pulmonary vascular resistance and attenuates pathological remodeling. The SERAPHIN Phase 3 trial confirmed that Macitentan significantly reduces morbidity and mortality in PAH, and the drug is now approved in over 80 countries under the brand name Opsumit®.

Pulmonary arteriovenous malformation (PAVM) is a fundamentally different disease: it is a structural vascular defect in which pulmonary arteries connect directly to pulmonary veins, bypassing the capillary bed entirely. This creates an anatomical right-to-left shunt without any known involvement of the ET-1 signaling pathway. The pathophysiology of PAVM is driven by embryological vascular development defects (often linked to hereditary hemorrhagic telangiectasia / HHT), not by vasoactive mediator imbalance. Accordingly, the standard of care is transcatheter embolization — a mechanical intervention to physically occlude the abnormal channel.

Macitentan's ERA mechanism has no direct intervention point on a structural shunt, and there is no preclinical or clinical precedent for ERA use in PAVM. The high TxGNN prediction score (98.89%) most plausibly reflects indirect knowledge graph proximity through shared "pulmonary vascular disease" ontology nodes — a recognized false-positive pattern in graph neural network drug repurposing models when target diseases share broad categorical overlap with an approved indication but diverge mechanistically.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: PAVM is a structural vascular malformation addressed by embolization; Macitentan's endothelin receptor antagonist mechanism lacks any pathophysiologically relevant target in this disease, and the high TxGNN score is assessed as a knowledge graph artifact rather than a clinically meaningful signal.

To proceed, the following is needed:

Preclinical evidence demonstrating ET-1 pathway involvement in PAVM pathogenesis (currently absent in the literature)
Published case series or mechanistic studies linking ERA therapy to PAVM outcomes

Priority recommendation — redirect evaluation to the following indications in this evidence pack, which have genuine mechanistic grounding and existing real-world evidence:

Rank	Indication	Evidence Level	Trials	Publications	Decision
#2	PAH associated with Congenital Heart Disease (CHD-PAH)	L3	2 (1 active Phase 3 platform: NCT05179876)	18 (incl. direct real-world cohort studies 2017–2026)	Proceed with Guardrails
#5	PAH associated with Connective Tissue Disease (CTD-PAH)	L3	2	18 (incl. systematic review PMID 38378970 + multiple real-world cohort studies 2022–2025)	Proceed with Guardrails

Both CHD-PAH and CTD-PAH share the same ET-1 overactivation pathway as idiopathic PAH, are formally classified as WHO Group 1 PAH, and already appear as subgroups in the SERAPHIN trial that established Macitentan's global approval. The real-world evidence base for these subtypes is active and growing. These are the highest-yield targets for a Singapore drug access or clinical development strategy.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.